Roche adds Galaxy FGF2 MAbs to complement internal project
This article was originally published in Scrip
Executive Summary
Roche has licensed exclusive worldwide development and commercialisation rights to Galaxy Biotech's antibodies targeting fibroblast growth factor 2 (FGF2) for the treatment of cancer.